drugset
drugset / Trial / NCT03913260

A Study of Different Injectable Formulations of LY3375880 in Healthy Participants

NCT03913260 ↗

Phase 1 Completed 83 enrolled Eli Lilly and Company
RandomizedCrossoverDouble-blindBasic science

Summary

The main purposes of this study are: 1. To learn more about the safety and side effects of different formulations of LY3375880 and 2. To measure how much LY3375880 gets into the blood stream and how long it takes to get out of the body. The study will last about 85 days. Screening may occur up to 28 days prior to enrollment.

Timeline

Start
2019-05-01
Primary completion
2019-09-19
Completion
2019-09-19

Drugs

EvaluationDrugModalityDoseRoute
Subject TORUDOKIMAB Monoclonal antibody — Subcutaneous

Indications

No indication recorded.